Wozu CaviTAU®

Ermittlung der Knochendichte mit CaviTAU® Ultraschalltechnologie beantwortet ohne Strahlenbelastung drei medizinisch notwendige Fragen:

a) Die Frage nach der Stabilität und Ausheilungsgrad des Knochenlagers bei geplanter Implantation.

(Siehe hierzu wissenschaftliche Untersuchungen/Publikationen:

1. Paquette DW, Brodala N, Williams RC. Risk factors for endosseous dental implant failure. Dent Clin North Am 2006;50:361-74 vi.

2. Reid IR. Osteonecrosis of the jaw: who gets it, and why? Bone 2009;44:4-10.

3. Lee S-C et al. Displacement of dental implants into the focal osteoporotic bone marrow defect: a report of three cases, Journal of the Korean Association of Oral and Maxillofacial Surgeons, 39, 2, (94), (2013).

4. Lee S, Gantes B, Riggs M, Crigger M (2007). “Bone density assessments of dental implant sites: 3. Bone quality evaluation during osteotomy and implant placement”. The International Journal of Oral & Maxillofacial Implants. 22 (2): 208–12. PMID 17465345.

5. Al-Nawas B, Grotz KA, Kann P. Ultrasound transmission velocity of the irradiated jaw bone in vivo. Clin Oral Invest 2001;5:266 –268.

6. M.O. Klein, K.A. Grotz, B. Manefeld, P.H. Kann and B. Al-Nawas, “Ultrasound transmission velocity for non-invasive evaluation of jaw bone quality in vivo prior to dental implantation”, Ultrasound in Medicine & Biology 2008, 34: 1966-1971.)

b) Die Frage nach der „silent inflammation“ im Knochenmark/Jawbone marrow defects/AIOK/“NICO“/FDOK mit lokaler RANTES/CCL5 Überexpression und systemisch-immunologischen Erkrankungen.

(Siehe hierzu wissenschaftliche Untersuchungen/Publikationen:

1. J. Bouquot, W. Martin and G. Wrobleski “Computer-based thru-transmission sonography (CTS) imaging of ischemic osteonecrosis of the jaws – a preliminary investigation of 6 cadaver jaws and 15 pain patients”, Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001, 92: 550.

2. J. Lechner and V. von Baehr, “RANTES and fibroblast growth factor 2 in jawbone cavitations: triggers for systemic disease?” International Journal of General Medicine 2013, 6: 277-290.

3. J. Lechner, S. Schuett and V. von Baehr, “Aseptic-avascular osteonecrosis: local `silent inflammation` in the jawbone and RANTES/CCL5 overexpression”, Clinical, Cosmetic and Investigational Dentistry 2017:9 99–109.

4. Lechner J, von Baehr V. Hyperactivated Signaling Pathways of Chemokine RANTES/CCL5 in Osteopathies of Jawbone in Breast Cancer Patients—Case Report and Research. Breast Cancer: Basic and Clinical Research 2014:8 89–96.

5. Lechner J, Rudi T, von Baehr V.Osteoimmunology of tumor necrosis factor-alpha, IL-6, and RANTES/CCL5: a review of known and poorly understood inflammatory patterns in osteonecrosis. Clinical, Cosmetic and Investigational Dentistry 2018:10 251—262. DOI (https://doi.org/10.2147/CCIDE.S184498.)

c) Die – bislang wenig untersuchte – Frage nach der nicht-exponierten Form der bisphosphonat-induzierten Osteonekrose (BONJ) ohne klinische Ausbildung von Knochensequestern.

(Siehe hierzu wissenschaftliche Untersuchungen/Publikationen:

1. Junquera L, Gallego L. Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant? J. Oral Maxillofac. Surg. 66(7), 1516–1517 (2008).

2. Fedele S, Porter SR, D’aiuto F et al. Nonexposed variant of bisphosphonate- associated osteonecrosis of the jaw: a case series. Am. J. Med. 123(11), 1060–1064 (2010).

3. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M et al (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.AnnOncol20(1):117–120

4. Grötz KA, Al-Nawas B. (2006) Persisting alveolar sockets–a radiologic symptom of BP-ONJ? J Oral Maxillofac Surg 64(10):1571–1572.

5. Lechner, J et al. Osteonecrosis of the Jaw beyond Bisphosphonates
– Are there any unknown local risk factors? (under review))